18F-FDG PET/CT与18F-FAPI PET/CT在新诊断乳腺癌全身分期中的比较
回顾性分析38例初诊临床IIB-IIIC期乳腺癌患者,均行18F-FAPI与18F-FDG PET/CT。18F-FAPI PET/CT总体升级率47.4%(18/38)高于18F-FDG的34.2%(13/38)。基于病灶分析,18F-FAPI对区域淋巴结转移和远处转移的敏感度均显著高于18F-FDG。
要点
- 18F-FAPI PET/CT总体升级率47.4%(18/38),高于18F-FDG PET/CT的34.2%(13/38)。
- 基于病灶分析,18F-FAPI对区域淋巴结转移敏感度97.6%(41/42)显著高于18F-FDG的52.4%(22/42)(P < 0.001)。
- 基于病灶分析,18F-FAPI对远处转移敏感度98.1%(51/52)显著高于18F-FDG的67.3%(35/52)(P < 0.001)。
核心结论
- 18F-FAPI PET/CT在新诊断乳腺癌中导致显著分期升级,升级率高于18F-FDG PET/CT;基于病灶分析对未被怀疑的转移灶敏感度显著更高,提示18F-FAPI PET/CT未来可能在评估转移性疾病负荷中发挥作用。
研究设计与样本
- 回顾性分析2022年6月至2023年6月间连续接受18F-FAPI和18F-FDG PET/CT的初诊临床IIB-IIIC期乳腺癌患者38例;以组织学或随访影像为参考标准,计算基于患者和基于病灶的敏感度。
诊断标准与关键数值
- 基于患者分析,18F-FAPI PET/CT检测区域淋巴结转移的敏感度为100%(13/13),18F-FDG PET/CT为53.8%(7/13),两者差异有统计学意义(P = 0.031)。
- 基于患者分析,18F-FAPI PET/CT检测远处转移的敏感度为100%(10/10),18F-FDG PET/CT为90%(9/10),两者差异无统计学意义(P = 1.000)。
- 基于病灶分析,18F-FAPI PET/CT检测区域淋巴结转移的敏感度为97.6%(41/42),18F-FDG PET/CT为52.4%(22/42),差异有统计学意义(P < 0.001)。
- 基于病灶分析,18F-FAPI PET/CT检测远处转移的敏感度为98.1%(51/52),18F-FDG PET/CT为67.3%(35/52),差异有统计学意义(P < 0.001)。
- 18F-FAPI PET/CT在IIB期患者中检出远处转移的比例为5.5%,IIIA期为30%,IIIB期为50%,IIIC期为75%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: The purpose of this study was to compare the performance of 18F-FAPI PET/CT and 18F-FDG PET/CT in systemic staging of newly diagnosed breast cancer.
METHODS: Breast cancer patients with initial clinical stage IIB-IIIC who have consequently underwent both 18F-FAPI and 18F-FDG PET/CT from June 2022 to June 2023 were retrospectively analyzed. New clinical stage was assigned to each patient if unsuspected level III axillary and extraaxillary regional lymph node metastases (URNM) and/or distant metastases were disclosed after PET/CT. Sensitivity for both tests was calculated on patient basis and lesion basis using histology or follow-up imaging as reference standard.
RESULTS: 38 patients were included. The overall upstaging rate was 47.4% for 18F-FAPI PET/CT (18/38) and 34.2% for 18F-FDG PET/CT (13/38). The rate of distant metastases disclosed by 18F-FAPI PET/CT was 5.5% in stage IIB patients, 30% in stage IIIA patients, 50% in stage IIIB patients, and 75% in stage IIIC patients. On patent-based analysis, the sensitivity of 18F-FAPI PET/CT was significantly different from that of 18F-FDG PET/CT in detecting URNM [100% (13/13) vs 53.8% (7/13), (P = 0.031)], but not for distant metastases [100% (10/10) vs 90% (9/10), (P = 1.000)]. On lesion-based analysis, the sensitivity of 18F-FAPI PET/CT was significantly higher than that of 18F-FDG PET/CT in detecting URNM [97.6% (41/42) vs 52.4% (22/42), (P < 0.001)] and distant metastases [98.1% (51/52) vs 67.3% (35/52), (P < 0.001)].
CONCLUSION: 18F-FAPI PET/CT leads to significant upstaging in newly diagnosed breast cancer, in a rate higher than 18F-FDG PET/CT. The significantly higher lesion-based sensitivity in unsuspected metastases implies a future role of 18F-FAPI PET/CT in evaluation of metastatic disease burden.
引用
- Bin J, Wenjia L, Wan W, et al. Comparison of 18F-FDG PET/CT and 18F-FAPI PET/CT in Systemic Staging of Newly Diagnosed Breast Cancer. Acad Radiol. 2024. PMID: 39242298. doi:10.1016/j.acra.2024.07.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。